Tuesday
February 7

7:30–8:00 Registration & Coffee Commonwealth Foyer

Meeting: Richmond/Roanoke

8:00–8:15 Opening Remarks
Matthew Fields
Director, CBE; Professor, Microbiology & Cell Biology, MSU
Paul Sturman, Industrial Coordinator, CBE

Keynote Presentation
8:15–9:00 OSEL Sterility and Infection Control Regulatory Science Program: A focus on stakeholder needs
Michael Eppihimer, Director, Division of Biology, Chemistry and Material Sciences, OSEL, CDRH, US FDA

SESSION 1: Reusable Medical Devices
9:00–9:30 Effect of protein concentration on biofilm formation in polytetrafluoroethylene tubing
Garth James, PI, Medical Biofilms Laboratory, CBE; Associate Research Professor, Chemical & Biological Engineering, MSU

9:30–10:00 Biofilm cleaning performance evaluation in automated endoscope reprocessors
Bruno Haas, Group Leader, Scientific, Research and Validation Team, STERIS

10:00–10:30 Break

10:30–11:00 Current state of flexible endoscope reprocessing: Why is build-up biofilm a concern?
Michelle Alfa, President, AlfaMed Consulting, Ltd.

11:00–11:30 Analyzing biofilm reduction for cleaning of medical device surfaces
Katie Segars, Assistant Director, Division of Biology, Chemistry, and Materials Science, OSEL, CDRH, US FDA

Panel Discussion
11:30–12:30 Assessing cleaning and disinfecting procedures for reusable medical devices to improve patient safety
Michelle Alfa
Bruno Haas
Garth James
Katie Segars
Laura Wahlen, Baxter Healthcare
Moderator: Darla Goeres, CBE

12:30–1:30 Lunch Will/York

SESSION 2: Bioremediation
1:30–2:10 Session Introduction
In situ bioremediation of selenium and nitrate for full scale treatment of mine waste
Brent Peyton, Professor, Chemical & Biological Engineering, MSU, CBE

2:10–2:40 Pharmaceutical effects on a novel wastewater treatment biotechnology
Kylie Bodile, PhD Student, Civil Eng., MSU, CBE

2:40–3:10 Break

3:10–3:40 Bioremediation—State of Practice—A ‘sampler’ for biofilm devotees
Jim Cummings, Program Analyst, US EPA

3:40–4:10 Biofilm considerations: Bioremediation of contaminated groundwater
Birthe Veno Kjellerup, Associate Professor, Civil & Environmental Eng., University of Maryland

4:10–4:40 Expedited organo-halide destruction via biostimulation without augmentation supported by introduction of abiotic electron donor
Kent Armstrong, President, TerraStryke Products LLC

5:00–6:30 Networking Reception Crystal Ballroom
Wednesday
February 8

7:45–8:20
Registration & Coffee
Commonwealth Foyer

SESSION 3: Emerging Surface Disinfection Methods

8:20–8:30
Session Introduction
Al Parker, Biostatistician, CBE; Associate Research Professor, Mathematical Sciences, MSU

8:30–9:00
An overview of EPA’s guidance and methods for adding residual efficacy claims
Rebecca Pines, Branch Chief, Microbiology Laboratory Branch, Office of Pesticide Programs, US EPA

8:30–9:00
An overview of EPA’s guidance and methods for adding residual efficacy claims
Rebecca Pines, Branch Chief, Microbiology Laboratory Branch, Office of Pesticide Programs, US EPA

9:00–9:30
Multiple multi-lab evaluations of the Quantitative Method for determining the efficacy of antimicrobial substances against bacteria dried onto hard non-porous surfaces
Al Parker

9:30–10:00
Industry perspectives on the Quantitative Method to measure disinfection efficacy: Progress to improve reproducibility and parameters for assessing suitability as a regulatory standard
John Hilgren, Director, Regulatory Affairs, Ecolab

11:00–11:30
New method for Legionella pneumophila claims in cooling tower water
Lisa Smith, Team Leader, Microbiology Laboratory Branch, Office of Pesticide Programs, US EPA

11:30–12:00
Good riddance—The importance of biofilm removal and the need for standardized methods
Bruce Urtz, Microbiology Manager, Sterilex

12:00–1:00 Lunch Will/York

SESSION 4: Global Perspectives on Biofilm Claims

1:00–1:10
Session Introduction
Darla Goeres, Research Professor of Regulatory Science, CBE

1:10–1:40
Antibiofilm surfaces in the built environment: Current methods and considerations for method development
James Redfern, Senior Lecturer, Natural Sciences, Manchester Metro University

1:40–2:10
Prevention and treatment of biofilms—Update on European method development and claims
Florian Brill, Managing Director, Dr. Brill + Partner, GmbH

2:10–2:40
The UK’s standpoint on biofilm claims and methods in the medical devices sector
Paulina Rakowska, Research and Innovation Development Manager, National Biofilms Innovation Centre (NBIC)

Save the Date!
2023 Montana Biofilm Meeting
July 11-13
Bozeman, MT